Adam M. Koppel
InvestorPartner at Bain Capital Life Sciences · Board director at Areteia Therapeutics · Board director at Cardurion Pharmaceuticals, Inc. · Board director at Solid Biosciences
Boston
Writes $100K – $5M checks · typically $1.5M
Find your path to Adam
929 people in our graph share verified history with Adam — schools, employers, funds. One of them is your warm intro.
About
Adam M. Koppel is a Partner on the Life Sciences team at Bain Capital, which he first joined in 2003 and rejoined in 2016, having earlier been part of the firm's Public Equity team focused on healthcare. Between his stints at Bain Capital, he served as EVP of Corporate Development and Chief Strategy Officer at Biogen, and prior to that was an Associate Principal at McKinsey & Company. He holds an MD and PhD in neuroscience and an MBA from the University of Pennsylvania, and an AB and AM in history and science from Harvard University.
Invests in
Biotech
Board director at Areteia Therapeutics
Intro paths
In turn, Adam can intro founders to Areteia Therapeutics's investors below.
Areteia Therapeutics's investors · 7
Board director at Cardurion Pharmaceuticals, Inc.
Intro paths
In turn, Adam can intro founders to Cardurion Pharmaceuticals, Inc.'s investors below.
Cardurion Pharmaceuticals, Inc.'s investors · 6
Board director at Solid Biosciences
Intro paths
In turn, Adam can intro founders to Solid Biosciences's investors below.
Solid Biosciences's investors · 3
Experience
- Bain CapitalManaging Directorcurrent2016 — presentBoston, MA
- BiogenEVP, Corporate Development & Strategy2014 — 2016Cambridge, MA
- Bain CapitalManaging Director2003 — 2014
- McKinsey & CompanyAssociate Principal2000 — 2004
Skills & more
+8 more
HealthcareFinancial ModelingStart-upsHedge FundsEquity ResearchPortfolio ManagementCompetitive AnalysisPharmaceutical IndustryFrom Adam's professional profile.
Deals · 4
Areteia TherapeuticsBoard seat
via Bain Capital Life Sciences · filed Feb 2025 · $445M raise
Cardurion Pharmaceuticals, Inc.Board seat
via Bain Capital Life Sciences · filed Jul 2023 · $128.1M raise
Solid BiosciencesBoard seat
via Bain Capital Life Sciences · filed Oct 2020 · $40M raise
AptinyxBoard seat
via Bain Capital Life Sciences · filed Dec 2017 · $70M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Bain Capital Life Sciences
Network7
Investors connected to Adam in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Adam M. Koppel?
- Adam M. Koppel is a Partner on the Life Sciences team at Bain Capital, which he first joined in 2003 and rejoined in 2016, having earlier been part of the firm's Public Equity team focused on healthcare. Between his stints at Bain Capital, he served as EVP of Corporate Development and Chief Strategy Officer at Biogen, and prior to that was an Associate Principal at McKinsey & Company. He holds an MD and PhD in neuroscience and an MBA from the University of Pennsylvania, and an AB and AM in history and science from Harvard University.
- Where does Adam M. Koppel work?
- Adam M. Koppel is Partner at Bain Capital Life Sciences and Board director at Areteia Therapeutics and Board director at Cardurion Pharmaceuticals, Inc. and Board director at Solid Biosciences.
- What does Adam M. Koppel invest in?
- Adam M. Koppel invests in Biotech.
- What check size does Adam M. Koppel write?
- Adam M. Koppel typically writes checks of $100K – $5M.
- What boards does Adam M. Koppel sit on?
- Adam M. Koppel holds tracked board seats at Aptinyx, Areteia Therapeutics, Cardurion Pharmaceuticals, Inc., Solid Biosciences.
- Where did Adam M. Koppel go to school?
- Adam M. Koppel studied at Harvard University; University of Pennsylvania School of Medicine (MD, PhD); The Wharton School (MBA, Finance).
Same school
Also attended Harvard University2,000
+ 1,994 more
Also attended University of Pennsylvania School of Medicine47
+ 41 more
Also attended The Wharton School2,000
+ 1,994 more
Shared employers
Also worked at Biogen42
+ 36 more
Also worked at Bain Capital267
+ 261 more
Also worked at McKinsey & Company2,000
.jpg)
+ 1,994 more